There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rocket Pharmaceuticals (RCKT – Research Report) and Treace Medical Concepts (TMCI – Research Report) with bullish sentiments.
Rocket Pharmaceuticals (RCKT)
In a report released today, Gil Blum from Needham maintained a Buy rating on Rocket Pharmaceuticals, with a price target of $62.00. The company’s shares closed last Tuesday at $13.69.
According to TipRanks.com, Blum ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Rocket Pharmaceuticals with a $46.25 average price target, which is a 237.6% upside from current levels. In a report released yesterday, Chardan Capital also reiterated a Buy rating on the stock with a $62.00 price target.
Treace Medical Concepts (TMCI)
In a report released today, Ryan Zimmerman from BTIG reiterated a Buy rating on Treace Medical Concepts, with a price target of $28.00. The company’s shares closed last Tuesday at $23.55.
According to TipRanks.com, Zimmerman is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Treace Medical Concepts with a $25.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RCKT:
- Important Milestone Reached for Evaxion Biotech’s EVX-01 Personalized Cancer Therapy
- CrowdStrike Holdings (CRWD) Gets a Buy from Needham
- Oil Rises as Putin Flexes Muscle Over Ukraine
- Needham Sticks to Its Buy Rating for Smartsheet (SMAR)
- Wells Fargo Keeps Their Buy Rating on Hartford Financial (HIG)